Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
SIMI VALLEY, California.—The White House has greenlit a plan to design and build a frigate domestically as part of its proposed “Golden Fleet,” Navy Secretary John Phelan announced at the Reagan ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Even before large pieces of the federal government shut down in October 2025, the Supplemental Nutrition Assistance Program, or SNAP – sometimes called the food stamp program – was in for some big ...
Eriez, an Erie, Pennsylvania-based magnetic separation and material handling technology company, has expanded its Quick Ship program to provide faster turnarounds for customers in North America. The ...
Albany International Initiates Review of Strategic Alternatives for Structures Assembly Business; Announces Loss Reserve Adjustment for CH-53K Program; Schedules Earnings Release Date Third-Quarter ...
Powered by 25 years of research, this program pairs patented nutrition technology with personalized medical nutrition to rebuild metabolic and heart health. LOS ANGELES, Oct. 23, 2025 /PRNewswire/ -- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback